Sumary of Vaccines and boosters remain strong against current SARS-CoV-2 variants:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the world, creating the coronavirus disease 2019 (COVID-19) pandemic, which has posed a significant threat to public health and the global economy.
- Several vaccines have been developed to counteract the pandemic, but SARS-CoV-2 variants of concern (VOCs) have been identified that have the potential to escape serum neutralization induced by the vaccines.
- In a recent study published in the Lancet Microbe journal, Australian researchers studied whether in-vitro neutralization titers could predict vaccine protection from SARS-CoV-2 variants.
- In some clinical trials, researchers have observed that the current vaccines may be less protective against symptomatic infection with some SARS-CoV-2 variants.
- There are also studies that show that antibody titers wane over time.
- Therefore, given the above observations, the critical question is regarding the extent to which current vaccines are likely to protect against emerging variants of concern.
- In previous research, scientists have reported a correlation between titers of neutralizing antibodies and protection from SARS-CoV-2 infection.
- They have also derived a model for predicting vaccine efficacy from mean neutralization titers.